JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Kodu・Aktsiate loetelu・Ovid therapeutics Inc
Search

Ovid therapeutics Inc

Suletud

SektorTervishoid

2.78 0.72

Tugev "osta" hinnang

Hinna uuendus 1. mai 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.76

Max

2.8

Põhinäitajad

By Trading Economics

Sissetulek

22M

9.7M

Müük

586K

718K

Kasumimarginaal

1,345.822

Töötajad

23

EBITDA

-152K

-12M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+71.67% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. mai 2026

Turustatistika

By TradingEconomics

Turukapital

327M

465M

Eelmine avamishind

2.06

Eelmine sulgemishind

2.78

Uudiste sentiment

By Acuity

78%

22%

330 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.275 / 0.33 Toetus ja vastupanu

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. mai 2026, 22:17 UTC

Tulu

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Loe

4. mai 2026, 23:47 UTC

Tulu

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Loe

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Loe

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Loe

4. mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Loe

4. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Loe

4. mai 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Loe

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Loe

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Loe

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Loe

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Loe

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Shareholders to Own About 51% of Combined Company

DJ

Loe

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Loe

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Deal Unanimously Recommended by Vault Board

DJ

Loe

4. mai 2026, 22:39 UTC

Omandamised, ülevõtmised, äriostud

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Loe

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Loe

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Loe

4. mai 2026, 22:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Loe

4. mai 2026, 22:26 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Loe

4. mai 2026, 22:02 UTC

Tulu

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Loe

4. mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Loe

4. mai 2026, 21:52 UTC

Tulu

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Loe

4. mai 2026, 21:50 UTC

Tulu

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Loe

4. mai 2026, 21:50 UTC

Tulu

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Loe

4. mai 2026, 21:49 UTC

Tulu

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Loe

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Loe

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Loe

4. mai 2026, 21:43 UTC

Tulu

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Loe

4. mai 2026, 21:41 UTC

Tulu

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Loe

4. mai 2026, 21:40 UTC

Tulu

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

71.67% tõus

12 kuu keskmine prognoos

Keskmine 5.03 USD  71.67%

Kõrge 7 USD

Madal 4 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

8

Osta

0

Hoia

0

Müü

Põhineb 8 analüütiku instrumendi Ovid therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.275 / 0.33Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Bullish Evidence

All events are bullish.

Pikk perspektiiv

Weak Bearish Evidence

There is one bearish event.

Sentiment

By Acuity

330 / 347 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Muud aktsiad sektorist

JNJ

Johnson and Johnson

225.57

↑ +0.63%

UNH

UnitedHealth Group Inc

363.82

↓-1.87%

TMO

Thermo Fisher Scientific Inc

466.62

↑ +0.92%

ISRG

Intuitive Surgical Inc

451.55

↓-0.21%

ABT

Abbott Laboratories

87.15

↓-0.47%
help-icon Live chat